Search
Descriptor English: Sunitinib
Descriptor Spanish: Sunitinib
Descriptor sunitinib
Entry term(s) (2-dietilaminoetil)amida del ácido 5-(5-fluoro-2-oxo-1,2-dihidroindolilidenemetil)-2,4-dimetil-1H-pirrol-3-carboxílico
SU 011248
SU 11248
SU-011248
SU-11248
SU011248
SU11248
Sutent
malato de sunitinib
Scope note: Derivado indólico y pirrólico que inhibe las TIROSINCINASAS VEGFR-2 y RECEPTOR BETA DEL PDGF. Se usa como antineoplásico para el tratamiento de los TUMORES DEL ESTROMA GASTROINTESTINAL y del CARCINOMA DE CÉLULAS RENALES avanzado o metastásico.
Descriptor Portuguese: Sunitinibe
Descriptor French: Sunitinib
Entry term(s): 5-(5-Fluoro-2-oxo-1,2-dihydroindolylidenemethyl)-2,4-dimethyl-1H-pyrrole-3-carboxylic acid (2-diethylaminoethyl)amide
SU 011248
SU 11248
SU-011248
SU-11248
SU011248
SU11248
Sunitinib Malate
Sutent
Tree number(s): D03.383.129.578.823
D03.633.100.473.877
RDF Unique Identifier: https://id.nlm.nih.gov/mesh/D000077210
Scope note: An indole and pyrrole derivative that inhibits VEGFR-2 and PDGFR BETA RECEPTOR TYROSINE KINASES. It is used as an antineoplastic agent for the treatment of GASTROINTESTINAL STROMAL TUMORS, and for treatment of advanced or metastatic RENAL CELL CARCINOMA.
Allowable Qualifiers: AA analogs & derivatives
AD administration & dosage
AE adverse effects
AG agonists
AI antagonists & inhibitors
AN analysis
BL blood
CF cerebrospinal fluid
CH chemistry
CL classification
CS chemical synthesis
EC economics
HI history
IM immunology
IP isolation & purification
ME metabolism
PD pharmacology
PK pharmacokinetics
PO poisoning
RE radiation effects
SD supply & distribution
ST standards
TO toxicity
TU therapeutic use
UR urine
Pharm Action: Antineoplastic Agents
Angiogenesis Inhibitors
Protein Kinase Inhibitors
Registry Number: V99T50803M
Public MeSH Note: 2019; SUNITINIB was indexed under INDOLES and PYRROLES 2003-2018
History Note: 2019 (2003)
DeCS ID: 57545
Unique ID: D000077210
Documents indexed in the Virtual Health Library (VHL): Click here to access the VHL documents
Date Established: 2019/01/01
Date of Entry: 2018/07/09
Revision Date: 2019/04/29
Sunitinib - Preferred
Concept UI M0448793
Scope note An indole and pyrrole derivative that inhibits VEGFR-2 and PDGFR BETA RECEPTOR TYROSINE KINASES. It is used as an antineoplastic agent for the treatment of GASTROINTESTINAL STROMAL TUMORS, and for treatment of advanced or metastatic RENAL CELL CARCINOMA.
Preferred term Sunitinib
Entry term(s) 5-(5-Fluoro-2-oxo-1,2-dihydroindolylidenemethyl)-2,4-dimethyl-1H-pyrrole-3-carboxylic acid (2-diethylaminoethyl)amide
Sunitinib Malate - Narrower
Concept UI M0496689
Preferred term Sunitinib Malate
Sutent - Narrower
Concept UI M0497993
Preferred term Sutent
SU 11248 - Narrower
Concept UI M0448794
Preferred term SU 11248
Entry term(s) SU 011248
SU-011248
SU-11248
SU011248
SU11248



We want your feedback on the new DeCS / MeSH website

We invite you to complete a survey that will take no more than 3 minutes.

Go to survey